On Nov. 18, 2021, CureVac announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK, in the journal Nature.

The published data featured a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnatyﾮ (Pfizer/BioNTech). Neutralizing antibody levels measured following full vaccination of animals with either 12ﾵg of CV2CoV or a 30ﾵg standard dose of Comirnatyﾮ were shown to be highly comparable.